4.3 Article

Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study

Journal

ONCOTARGET
Volume 8, Issue 55, Pages 93957-93968

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.21398

Keywords

network pharmacology; drug repurposing; TCMs; pathway profile; LDW

Funding

  1. National Nature Science Foundation of China [61772368, 61572363, 91530321, 61602347, 81573702, 31671374]
  2. Ministry of Science and Technology's high-tech (863) grant [2014AA021502]
  3. Sino-German Research Center grant [GZ878]
  4. China Postdoctoral Science Foundation Funded Project [2016M601647]
  5. City University of Hong Kong [7004707]

Ask authors/readers for more resources

With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available